Rock Creek Group, LP Revance Therapeutics, Inc. Transaction History

Rock Creek Group, LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 15, 2020	SELL	$12.46 - $27.81 $186,900 - $417,150	-15,000 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$11.66 - $20.15 $40,810 - $70,525	-3,500 Reduced 18.92%	15,000 $243,000
Q3 2019 Nov 13, 2019	BUY	$10.22 - $14.5 $35,770 - $50,750	3,500 Added 23.33%	18,500 $241,000
Q2 2019 Aug 14, 2019	BUY	$10.67 - $15.49 $160,050 - $232,350	15,000 New	15,000 $195,000

234

82.8M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Rock Creek Group, LP, based on Form 13F filings with the SEC.

Stay updated on Rock Creek Group, LP with notifications on news.